Biogen (BIIB) is $60 billion market cap company focused on treating diseases of the central nervous system and neurodegeneration. The company has the leading portfolio of drugs to treat multiple sclerosis (MS) and has the only approved treatment for spinal muscular atrophy (SMA). The company is in development of treatments for neurodegenerative conditions such as Alzheimer's disease (AD), Parkinson's (PD), and amyotrophic lateral sclerosis (ALS). The company is exploring gene therapy and gene editing technologies in collaboration with University of Pennsylvania for therapies for ocular, muscular, and central nervous system tissues. BIIB also manufactures biosimilars, which offers cost savings thereby alleviating healthcare system economic burden. In Q1 2017 Biogen separated its global hemophilia business into a new company known as Bioverativ (BIVV), now a $6 billion market cap company. The company, with its most advanced candidates in phase 2 and phase 3 for AD, has a robust pipeline.

READ FULL ARTICLE HERE